Brentuximab vedotin exerts profound antiproliferative and pro-apoptotic efficacy in CD30-positive as well as cocultured CD30-negative germ cell tumour cell lines

Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models

(2016) F. Li et al.   CANCER RESEARCH

Brentuximab Vedotin in CD30-Expressing Germ Cell Tumors After Chemotherapy Failure

(2016) Andrea Necchi et al.   Clinical Genitourinary Cancer

Specific immune cell and cytokine characteristics of human testicular germ cell neoplasia

(2016) Britta Klein et al.   HUMAN REPRODUCTION

The bromodomain inhibitor JQ1 triggers growth arrest and apoptosis in testicular germ cell tumours in vitro and in vivo

(2016) Sina Jostes et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry

(2016) Nancy L. Bartlett et al.   LEUKEMIA & LYMPHOMA

Brentuximab vedotin in combination with extended field radiotherapy as salvage treatment for primary refractory Hodgkin lymphoma

(2015) Massimo Dozzo et al.   AMERICAN JOURNAL OF HEMATOLOGY

Guidelines on Testicular Cancer: 2015 Update

(2015) Peter Albers et al.   EUROPEAN UROLOGY

CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin

(2015) R. Chen et al.   MOLECULAR CANCER THERAPEUTICS

Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia

(2015) Zainul S. Hasanali et al.   Science Translational Medicine

BMP Inhibition in Seminomas Initiates Acquisition of Pluripotency via NODAL Signaling Resulting in Reprogramming to an Embryonal Carcinoma

(2015) Daniel Nettersheim et al.   PLoS Genetics

Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin

(2014) S. M. Horwitz et al.   BLOOD

Combination therapy with brentuximab vedotin and cisplatin/cytarabine in a patient with primarily refractory anaplastic lymphoma kinase positive anaplastic large cell lymphoma

(2014) Simon Heidegger et al.   OncoTargets and Therapy

Persistent CD30 Expression by Embryonal Carcinoma in the Treatment Time Course: Prognostic Significance of a Worthwhile Target for Personalized Treatment

(2013) Patrizia Giannatempo et al.   JOURNAL OF UROLOGY

Analysis of TET Expression/Activity and 5mC Oxidation during Normal and Malignant Germ Cell Development

(2013) Daniel Nettersheim et al.   PLoS One

U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma

(2012) R. A. de Claro et al.   CLINICAL CANCER RESEARCH

The Contemporary Role of Chemotherapy for Advanced Testis Cancer: A Systematic Review of the Literature

(2012) Fabio Calabrò et al.   EUROPEAN UROLOGY

EPCAM-A novel molecular target for the treatment of pediatric and adult germ cell tumors

(2012) Stefan Schönberger et al.   GENES CHROMOSOMES & CANCER

Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate

(2010) N. M. Okeley et al.   CLINICAL CANCER RESEARCH

Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

(2010) Anas Younes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Analysis of the adenomatous polyposis coli (APC) gene in childhood and adolescent germ cell tumors

(2010) Vera Okpanyi et al.   PEDIATRIC BLOOD & CANCER

Susceptibility of human T-cell leukemia virus type I-infected cells to humanized anti-CD30 monoclonal antibodies in vitro and in vivo

(2009) Naoyoshi Maeda et al.   CANCER SCIENCE

Testicular mixed germ cell tumors: a morphological and immunohistochemical study using stem cell markers, OCT3/4, SOX2 and GDF3, with emphasis on morphologically difficult-to-classify areas

(2009) Anuradha Gopalan et al.   MODERN PATHOLOGY